Regulatory News ODAC votes in favor of two CAR T-cell therapies for MM after weighing FDA concerns about early deaths March 22, 2024Vol.50 No.12By Jacquelyn Cobb and Paul Goldberg
NCI Rathmell announces new cancer screening network, new NCI virtual clinical trials office March 22, 2024Vol.50 No.12By Matthew Bin Han Ong
U.S., Sweden sign cancer research and innovation pact as part of preparedness plan for potential Russian aggression March 22, 2024Vol.50 No.12By Matthew Bin Han Ong
Cancer History ProjectConversation with The Cancer LetterFree Weeks before death from sarcoma, Norm Coleman reflected on his career in radiation oncology and addressing health disparities March 22, 2024Vol.50 No.12By Otis W. Brawley, Alexandria Carolan and Paul Goldberg
FreeGuest Editorial The global health contributions of Norm Coleman March 22, 2024Vol.50 No.12By Nina Wendling and Donna M. O’Brien
Conversation with The Cancer LetterRegulatory News FDA’s Harpreet Singh: Overall survival data tells the full story of immune checkpoint inhibitor benefit in NSCLCPooled analysis finds correlations between early endpoints and OS in ICI trials March 15, 2024Vol.50 No.11By Matthew Bin Han Ong and Paul Goldberg
Regulatory News ODAC gives thumbs-up to imetelstat for MDS, upholding the value of transfusion independence March 15, 2024Vol.50 No.11By Jacquelyn Cobb and Paul Goldberg
White House Biden’s FY25 budget requests $522M increase for NCI, $1.5B for ARPA-H, $2.9B for Moonshot March 15, 2024Vol.50 No.11By Alexandria Carolan
Guest Editorial How to navigate early clinical development and support robust registrational strategy and late-stage development in oncology March 15, 2024Vol.50 No.11By Tanja Obradovic
FreeIn the Archives Women’s History Month: How women in oncology are fighting for cultural change March 15, 2024Vol.50 No.11
